$VRNA
Verona Pharma PLC Stock $vrna

$vrna Overview Financials Valuation SEC Filings Company Website

2021 Form 10-K Financial Statement

#000165731222000010 Filed on March 03, 2022

Income Statement

Concept	2021	2020 Q4	2020
Revenue	$40.00M	$0.00	$0.00
YoY Change
Cost Of Revenue	$0.00
YoY Change
Gross Profit	$40.00M
YoY Change
Gross Profit Margin	100.0%
Selling, General & Admin	$33.91M	$6.730M	$29.77M
YoY Change	13.9%	1718.92%	198.0%
% of Gross Profit	84.77%
Research & Development	$79.41M	$8.650M	$44.51M
YoY Change	78.42%	-491.4%	4.92%
% of Gross Profit	198.52%
Depreciation & Amortization	$629.0K	$30.00K	$623.0K
YoY Change	0.96%	-81.25%	22.16%
% of Gross Profit	1.57%
Operating Expenses	$113.3M	$15.38M	$74.28M
YoY Change	52.55%	-935.87%	41.74%
Operating Profit	-$73.31M		-$74.28M
YoY Change	-1.3%		41.74%
Interest Expense	$340.0K	$410.0K	$35.00K
YoY Change	871.43%	-115.07%
% of Operating Profit
Other Income/Expense, Net	$17.73M	$10.00M	$9.277M
YoY Change	91.07%	6.04%	-22.13%
Pretax Income	-$55.59M	-$4.970M	-$65.00M
YoY Change	-14.48%	-158.2%	60.54%
Income Tax	-$18.00K	$7.400M	$146.0K
% Of Pretax Income
Net Earnings	-$55.57M	-$12.36M	-$65.15M
YoY Change	-14.7%	921.49%	60.61%
Net Earnings / Revenue	-138.92%
Basic Earnings Per Share	-$0.12
Diluted Earnings Per Share	-$117.4K	-$27.18K	-$250.0K
COMMON SHARES
Basic Shares Outstanding	473.2M shares
Diluted Shares Outstanding	473.2M shares

Balance Sheet

Concept	2021	2020 Q4	2020
SHORT-TERM ASSETS
Cash & Short-Term Investments	$148.4M	$188.0M	$188.0M
YoY Change	-21.07%	360.78%	360.78%
Cash & Equivalents	$148.4M	$188.0M	$188.0M
Short-Term Investments		$0.00	$0.00
Other Short-Term Assets	$6.100M	$1.720M	$6.200M
YoY Change	-1.61%	-14.89%	67.57%
Inventory
Prepaid Expenses		$4.538M
Receivables		$0.00
Other Receivables
Total Short-Term Assets	$170.1M	$202.5M	$202.5M
YoY Change	-16.02%	272.95%	272.93%
LONG-TERM ASSETS
Property, Plant & Equipment	$979.0K	$107.0K	$1.200M
YoY Change	-18.42%	69.84%	-14.29%
Goodwill		$545.0K
YoY Change		-6.84%
Intangibles
YoY Change
Long-Term Investments	$15.00M
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$16.52M	$1.702M	$1.700M
YoY Change	872.0%	-12.09%	-10.53%
TOTAL ASSETS
Total Short-Term Assets	$170.1M	$202.5M	$202.5M
Total Long-Term Assets	$16.52M	$1.702M	$1.700M
Total Assets	$186.6M	$204.2M	$204.2M
YoY Change	-8.63%	263.14%	263.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.04M	$178.0K	$200.0K
YoY Change	4922.0%	-90.78%	-89.47%
Accrued Expenses	$22.90M	$10.86M	$11.70M
YoY Change	95.76%	21.09%	21.88%
Deferred Revenue		$0.00
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$33.42M	$14.20M	$14.20M
YoY Change	135.37%	10.61%	10.94%
LONG-TERM LIABILITIES
Long-Term Debt	$4.874M	$4.635M	$4.600M
YoY Change	5.96%
Other Long-Term Liabilities	$286.0K	$500.0K	$500.0K
YoY Change	-42.8%	-28.57%	-28.57%
Total Long-Term Liabilities	$5.160M	$5.149M	$5.100M
YoY Change	1.18%	689.72%	628.57%
TOTAL LIABILITIES
Total Short-Term Liabilities	$33.42M	$14.20M	$14.20M
Total Long-Term Liabilities	$5.160M	$5.149M	$5.100M
Total Liabilities	$38.58M	$19.35M	$19.40M
YoY Change	98.88%	43.42%	43.7%
SHAREHOLDERS EQUITY
Retained Earnings		-$207.1M
YoY Change		46.04%
Common Stock		$31.79M
YoY Change		337.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$1.700M
YoY Change
Treasury Stock Shares
Shareholders Equity	$148.0M	$184.9M	$184.9M
YoY Change
Total Liabilities & Shareholders Equity	$186.6M	$204.2M	$204.2M
YoY Change	-8.63%	263.14%	263.35%

Cashflow Statement

Concept	2021	2020 Q4	2020
OPERATING ACTIVITIES
Net Income	-$55.57M	-$12.36M	-$65.15M
YoY Change	-14.7%	921.49%	60.61%
Depreciation, Depletion And Amortization	$629.0K	$30.00K	$623.0K
YoY Change	0.96%	-81.25%	22.16%
Cash From Operating Activities	-$33.25M	-$12.44M	-$45.08M
YoY Change	-26.23%	6.78%	5.15%
INVESTING ACTIVITIES
Capital Expenditures	$12.00K	$300.0K	$82.00K
YoY Change	-85.37%	42.86%	54.72%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$2.890M	$9.790M
YoY Change	-100.0%	52.91%	-79.33%
Cash From Investing Activities	-$12.00K	-$2.590M	$9.710M
YoY Change	-100.12%	53.25%	-79.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$733.0K		$200.2M
YoY Change	-99.63%
Debt Paid & Issued, Net	$0.00
YoY Change
Cash From Financing Activities	-$6.117M	-46.21M	$192.3M
YoY Change	-103.18%	-12260.53%
NET CHANGE
Cash From Operating Activities	-$33.25M	-12.44M	-$45.08M
Cash From Investing Activities	-$12.00K	-2.590M	$9.710M
Cash From Financing Activities	-$6.117M	-46.21M	$192.3M
Net Change In Cash	-$39.61M	-61.24M	$157.6M
YoY Change	-125.14%	372.53%	2938.73%
FREE CASH FLOW
Cash From Operating Activities	-$33.25M	-$12.44M	-$45.08M
Capital Expenditures	$12.00K	$300.0K	$82.00K
Free Cash Flow	-$33.27M	-$12.74M	-$45.16M
YoY Change	-26.33%	7.42%	5.21%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001657312
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-38067
CY2021	dei	Entity Registrant Name EntityRegistrantName	Verona Pharma plc
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	X0
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1489389
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	3 More London Riverside
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	London
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	SE1 2RE
CY2021	dei	Entity Address Country EntityAddressCountry	GB
CY2021	dei	Country Region CountryRegion	44
CY2021	dei	City Area Code CityAreaCode	203
CY2021	dei	Local Phone Number LocalPhoneNumber	283 4200
CY2021	dei	Security12b Title Security12bTitle	Ordinary shares, nominal value £0.05 per share*
CY2021	dei	Trading Symbol TradingSymbol	VRNA
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4538000	USD
CY2021Q4	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	15583000	USD
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	251300000	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	482944390	shares
CY2021	dei	Auditor Firm AuditorFirmId	876
CY2021	dei	Auditor Firm AuditorFirmId	876
CY2021	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2021	dei	Auditor Location AuditorLocation	Reading, United Kingdom
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	148380000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	187986000	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4037000	USD
CY2020Q4	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	8260000	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2063000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1720000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	170063000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	202504000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	80000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	107000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	545000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	545000	USD
CY2021Q4	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	15000000	USD
CY2020Q4	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	0	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	899000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1050000	USD
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	16524000	USD
CY2020Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	1702000	USD
CY2021Q4	us-gaap	Assets Assets	186587000	USD
CY2020Q4	us-gaap	Assets Assets	204206000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10044000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	178000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	22256000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10863000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	648000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	798000	USD
CY2021Q4	vrna	Warrant Liability Current WarrantLiabilityCurrent	0	USD
CY2020Q4	vrna	Warrant Liability Current WarrantLiabilityCurrent	2246000	USD
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	147000	USD
CY2020Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	0	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	327000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	118000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	33422000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14203000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4874000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4635000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	286000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	514000	USD
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5160000	USD
CY2020Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5149000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	38582000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	19352000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	489177550	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	488304446	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	480082966	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	463304446	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	31855000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	31794000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	385070000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	366411000	USD
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	603000	USD
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1700000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	79406000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44505000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4601000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4601000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-263716000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-207050000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	148005000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	184854000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	186587000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	204206000	USD
CY2021	us-gaap	Revenues Revenues	40000000	USD
CY2020	us-gaap	Revenues Revenues	0	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	33907000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	29772000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	113313000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	74277000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-73313000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-74277000	USD
CY2021	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	15630000	USD
CY2020	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	8267000	USD
CY2021	us-gaap	Investment Income Net InvestmentIncomeNet	14000	USD
CY2020	us-gaap	Investment Income Net InvestmentIncomeNet	121000	USD
CY2021	us-gaap	Interest Expense InterestExpense	340000	USD
CY2020	us-gaap	Interest Expense InterestExpense	35000	USD
CY2021	vrna	Unrealized Gain Loss On Warrants UnrealizedGainLossOnWarrants	2246000	USD
CY2020	vrna	Unrealized Gain Loss On Warrants UnrealizedGainLossOnWarrants	-1136000	USD
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	176000	USD
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2060000	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	17726000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9277000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-55587000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-65000000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-18000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	146000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-55569000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-65146000	USD
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2321000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-55569000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-67467000	USD
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	42741000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-65146000	USD
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2321000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	187360000	USD
CY2020	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	43000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	22177000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	184854000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-55569000	USD
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	733000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	25425000	USD
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	6850000	USD
CY2021	vrna	Adjustments To Additional Paid In Capital Reclassification From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation	588000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	148005000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-55569000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-65146000	USD
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	176000	USD
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2060000	USD
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	114000	USD
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	10000	USD
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	125000	USD
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	8000	USD
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2246000	USD
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1136000	USD
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	USD
CY2020	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	289000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	25425000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	22177000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	629000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	623000	USD
CY2021	vrna	Increase Decrease In Equity Interest Receivable IncreaseDecreaseInEquityInterestReceivable	15000000	USD
CY2020	vrna	Increase Decrease In Equity Interest Receivable IncreaseDecreaseInEquityInterestReceivable	0	USD
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-501000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	3065000	USD
CY2021	vrna	Increase Decrease In Tax And Tax Credit Receivables Current IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent	6924000	USD
CY2020	vrna	Increase Decrease In Tax And Tax Credit Receivables Current IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent	-768000	USD
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	343000	USD
CY2020	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-187000	USD
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	440000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	703000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	9866000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1398000	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	11389000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1940000	USD
CY2021	vrna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-373000	USD
CY2020	vrna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	110000	USD
CY2021	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	147000	USD
CY2020	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	0	USD
CY2021	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-379000	USD
CY2020	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	48000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-33254000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-45076000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	12000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	82000	USD
CY2021	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	0	USD
CY2020	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	9792000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-12000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	9710000	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	733000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	200156000	USD
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	12748000	USD
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	5000000	USD
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	108000	USD
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	6850000	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	43000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-6117000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	192343000	USD
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-223000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	581000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-39606000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	157558000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	187986000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30428000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	148380000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	187986000	USD
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1000	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	8000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	215000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	7000	USD
CY2021	vrna	Number Of Wholly Owned Subsidiaries NumberOfWhollyOwnedSubsidiaries	1	subsidiary
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-263700000	USD
CY2021	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	873104	shares
CY2021Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.86
CY2021	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	700000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses, the fair value of share-based compensation, the fair value of warrants and the fair value of the equity interest received under the Nuance Agreement (as defined below). Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from the Company’s estimates.</span></div>
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4538000	USD
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Concentration of credit risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Financial instruments that potentially subject the Company to concentration of credit risk consist of principally cash and cash equivalents, bank deposits and certain receivables. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company holds cash and cash equivalents with highly rated financial institutions and in highly rated money market funds and the Company has not experienced any significant credit losses in these accounts and does not believe the Company is exposed to any significant credit risk on these instruments.</span></div>
CY2021Q4	vrna	Prepaid Research And Development Fees Current PrepaidResearchAndDevelopmentFeesCurrent	2169000	USD
CY2020Q4	vrna	Prepaid Research And Development Fees Current PrepaidResearchAndDevelopmentFeesCurrent	2551000	USD
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1555000	USD
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1701000	USD
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	313000	USD
CY2020Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	286000	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4037000	USD
CY2021Q4	vrna	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	15583000	USD
CY2020Q4	vrna	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	8202000	USD
CY2021Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	0	USD
CY2020Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	58000	USD
CY2021Q4	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	15583000	USD
CY2020Q4	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	8260000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.08
CY2021Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P1Y9M18D
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	655000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	276000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	38000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	969000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	35000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	934000	USD
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	651000	USD
CY2020Q4	vrna	Accrued Professional Fees Listing And General Corporate Costs Current AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent	2149000	USD
CY2021Q4	vrna	Accrued Research And Development Fees Current AccruedResearchAndDevelopmentFeesCurrent	21336000	USD
CY2020Q4	vrna	Accrued Research And Development Fees Current AccruedResearchAndDevelopmentFeesCurrent	8607000	USD
CY2021Q4	vrna	Accrued Professional Fees Listing And General Corporate Costs Current AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent	919000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	107000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	22256000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10863000	USD
CY2016Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	31115926	shares
CY2016Q4	vrna	Class Of Warrant Or Right Issue Price Of Warrants Or Rights ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights	1.4365
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-55569000	USD
CY2016Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	0.4	shares
CY2016Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.7238
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	31003155	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	12401262	shares
CY2020	vrna	Class Of Warrant Or Right Number Of Exercised Or Forfeited ClassOfWarrantOrRightNumberOfExercisedOrForfeited	0	shares
CY2021	vrna	Class Of Warrant Or Right Number Of Exercised Or Forfeited ClassOfWarrantOrRightNumberOfExercisedOrForfeited	0	shares
CY2021Q4	vrna	Class Of Warrant Or Right Intrinsic Value ClassOfWarrantOrRightIntrinsicValue	0	USD
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	12401262	shares
CY2020Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	12401262	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.7238
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.7238
CY2021Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P0Y3M29D
CY2020Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P1Y3M29D
CY2021Q4	vrna	Warrant Liability Current WarrantLiabilityCurrent	0	USD
CY2021Q4	vrna	Sensitivity Analysis Of Fair Value Warrant Liability Impact Of10 Percent Increase In Volatility Rate SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentIncreaseInVolatilityRate	4000	USD
CY2021Q4	vrna	Warrant Liability Fair Value WarrantLiabilityFairValue	0	USD
CY2021Q4	vrna	Sensitivity Analysis Of Fair Value Warrant Liability Impact Of10 Percent Decrease In Volatility Rate SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentDecreaseInVolatilityRate	0	USD
CY2020Q4	vrna	Warrant Liability Current WarrantLiabilityCurrent	2246000	USD
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	2246000	USD
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1188000	USD
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-2246000	USD
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	1114000	USD
CY2021	vrna	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Foreign Exchange Difference FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeDifference	0	USD
CY2020	vrna	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Foreign Exchange Difference FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeDifference	22000	USD
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Other Comprehensive Income FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome	0	USD
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Other Comprehensive Income FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome	-78000	USD
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0	USD
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	2246000	USD
CY2020Q4	us-gaap	Income Tax Examination Penalties Accrued IncomeTaxExaminationPenaltiesAccrued	0	USD
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	274000	USD
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	315000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	4850000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	3191000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-60437000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-68191000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-55587000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-65000000	USD
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-18000	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	146000	USD
CY2021	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-18000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	146000	USD
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2021Q4	us-gaap	Income Tax Examination Penalties Accrued IncomeTaxExaminationPenaltiesAccrued	0	USD
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-18000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	146000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.190
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.190
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.075
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.089
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.109
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.048
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.026
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.004
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.030
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.059
CY2021	vrna	Effective Income Tax Rate Reconciliation Capital Allowances Percent EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent	-0.001
CY2020	vrna	Effective Income Tax Rate Reconciliation Capital Allowances Percent EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.001
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.002
CY2021Q4	vrna	Deferred Tax Liabilities Contingent Liability DeferredTaxLiabilitiesContingentLiability	8903000	USD
CY2020Q4	vrna	Deferred Tax Liabilities Contingent Liability DeferredTaxLiabilitiesContingentLiability	5860000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	8903000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	5860000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	26931000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	19855000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	7992000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	5631000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4228000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	10480000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	215000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	39155000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	36181000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	30252000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	30321000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	104300000	USD
CY2020Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	95700000	USD
CY2021	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
CY2020Q4	us-gaap	Income Tax Examination Interest Accrued IncomeTaxExaminationInterestAccrued	0	USD
CY2021Q4	us-gaap	Income Tax Examination Interest Accrued IncomeTaxExaminationInterestAccrued	0	USD
CY2020	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25425000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22177000	USD
CY2021Q4	dei	Entity Listing Depository Receipt Ratio EntityListingDepositoryReceiptRatio	8	Rate
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14179196	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.53
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2096285	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.73
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2506017	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.53
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	589128	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	1.93
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	54664	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.75
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13125672	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.41
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M18D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	914000	USD
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.06
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1696000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.72
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2126472	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12695200	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.38
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	950000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	10177240	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.53
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y1M6D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	553000	USD
CY2021Q4	dei	Entity Listing Depository Receipt Ratio EntityListingDepositoryReceiptRatio	8	Rate
CY2021	vrna	Share Based Compensation Arrangement By Share Based Payment Award Grants In Period Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue	3100000	USD
CY2020	vrna	Share Based Compensation Arrangement By Share Based Payment Award Grants In Period Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue	62100000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-65146000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-55569000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-65146000	USD
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	16200000	USD
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y6M
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-55569000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-65146000	USD
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	473188457	shares
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	262932653	shares
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	63443814	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	87519294	shares

Files In Submission

Name	View Source	Status
0001657312-22-000010-index-headers.html	Edgar Link	pending
0001657312-22-000010-index.html	Edgar Link	pending
0001657312-22-000010.txt	Edgar Link	pending
0001657312-22-000010-xbrl.zip	Edgar Link	pending
consentletter-fy21.htm	Edgar Link	pending
exhibit211q421.htm	Edgar Link	pending
exhibit311q421.htm	Edgar Link	pending
exhibit312q421.htm	Edgar Link	pending
exhibit321q421.htm	Edgar Link	pending
exhibit322q421.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
reguslease_139142144xend.htm	Edgar Link	pending
reguslease_139142144xend001.jpg	Edgar Link	pending
reguslease_145a151xendin.htm	Edgar Link	pending
reguslease_145a151xendin001.jpg	Edgar Link	pending
report.css	Edgar Link	pending
secondamendmenttoloanandse.htm	Edgar Link	pending
Show.js	Edgar Link	pending
veronapharmaincbriercree.htm	Edgar Link	pending
veronapharmaincbriercree001.jpg	Edgar Link	pending
veronapharmaincbriercree002.jpg	Edgar Link	pending
veronapharmaincbriercree003.jpg	Edgar Link	pending
veronapharmaincbriercree004.jpg	Edgar Link	pending
veronapharmaincbriercree005.jpg	Edgar Link	pending
veronapharmaincbriercree006.jpg	Edgar Link	pending
veronapharmaincbriercree007.jpg	Edgar Link	pending
veronapharmaincbriercree008.jpg	Edgar Link	pending
veronapharmaincbriercree009.jpg	Edgar Link	pending
veronapharmaincbriercree010.jpg	Edgar Link	pending
veronapharmaincbriercree011.jpg	Edgar Link	pending
veronapharmaincbriercree012.jpg	Edgar Link	pending
veronapharmaincbriercree013.jpg	Edgar Link	pending
veronapharmaincbriercree014.jpg	Edgar Link	pending
veronapharmaincbriercree015.jpg	Edgar Link	pending
veronapharmaincbriercree016.jpg	Edgar Link	pending
veronapharmaincbriercree017.jpg	Edgar Link	pending
veronapharmaincbriercree018.jpg	Edgar Link	pending
veronapharmaincbriercree019.jpg	Edgar Link	pending
veronapharmaincbriercree020.jpg	Edgar Link	pending
veronapharmaincbriercree021.jpg	Edgar Link	pending
veronapharmaincbriercree022.jpg	Edgar Link	pending
veronapharmaincbriercree023.jpg	Edgar Link	pending
veronapharmaincbriercree024.jpg	Edgar Link	pending
veronapharmaincbriercree025.jpg	Edgar Link	pending
veronapharmaincbriercree026.jpg	Edgar Link	pending
veronapharmaincbriercree027.jpg	Edgar Link	pending
veronapharmaincbriercree028.jpg	Edgar Link	pending
veronapharmaincbriercree029.jpg	Edgar Link	pending
veronapharmaincbriercree030.jpg	Edgar Link	pending
veronapharmaincbriercree031.jpg	Edgar Link	pending
veronapharmaincbriercree032.jpg	Edgar Link	pending
veronapharmaincbriercree033.jpg	Edgar Link	pending
veronapharmaincbriercree034.jpg	Edgar Link	pending
veronapharmaincbriercree035.jpg	Edgar Link	pending
veronapharmaincbriercree036.jpg	Edgar Link	pending
veronapharmaincbriercree037.jpg	Edgar Link	pending
veronapharmaincbriercree038.jpg	Edgar Link	pending
veronapharmaincbriercree039.jpg	Edgar Link	pending
veronapharmaincbriercree040.jpg	Edgar Link	pending
veronapharmaincbriercree041.jpg	Edgar Link	pending
veronapharmaincbriercree042.jpg	Edgar Link	pending
veronapharmaincbriercree043.jpg	Edgar Link	pending
veronapharmaincbriercree044.jpg	Edgar Link	pending
veronapharmaincbriercree045.jpg	Edgar Link	pending
veronapharmaincbriercree046.jpg	Edgar Link	pending
veronapharmaincbriercree047.jpg	Edgar Link	pending
veronapharmaincbriercree048.jpg	Edgar Link	pending
veronapharmaincbriercree049.jpg	Edgar Link	pending
veronapharmaincbriercree050.jpg	Edgar Link	pending
vrna-20211231.htm	Edgar Link	pending
vrna-20211231.xsd	Edgar Link	pending
vrna-20211231_cal.xml	Edgar Link	unprocessable
vrna-20211231_def.xml	Edgar Link	unprocessable
vrna-20211231_g1.jpg	Edgar Link	pending
vrna-20211231_g2.jpg	Edgar Link	pending
vrna-20211231_g3.jpg	Edgar Link	pending
vrna-20211231_g4.jpg	Edgar Link	pending
vrna-20211231_htm.xml	Edgar Link	completed
vrna-20211231_lab.xml	Edgar Link	unprocessable
vrna-20211231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VRNA
Verona Pharma PLC Stock $vrna

2021 Form 10-K Financial Statement

#000165731222000010 Filed on March 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRNA Verona Pharma PLC Stock $vrna

2021 Form 10-K Financial Statement

#000165731222000010 Filed on March 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRNA
Verona Pharma PLC Stock $vrna